Skip to main content

GSK plc (GSK) Stock Forecast

Data as of Sep 20, 2026

Healthcare · Current price $50.13 (-1.81%)

Consensus Target
$52.45
Upside
+19.7%
Analysts
1
Rating
Sell(4.00)

Price Target Range

Low $35.25Consensus $52.45High $85.00
▲ Current $50.13

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

No ratings in the last 3 months.
Strong Buy0
Buy0
Hold0
Sell0
Strong Sell0

6-Month Trend

No rating trend data.

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

No analyst price targets available.

GSK vs Sector & Market

MetricGSKHealthcare AvgLarge Cap Avg
Analyst Rating4.002.252.42
Analyst Count1818
Target Upside+19.7%+22243.7%+21.5%
P/E Ratio14.263.7538.34

Revenue Estimates

PeriodLowAvgHigh#
2026-09-30$11.44B$12.04B$12.40B2
2026-12-31$11.45B$12.06B$12.42B2
2027-03-31$10.32B$10.87B$11.20B2
2027-06-30$11.07B$11.66B$12.00B2
2027-09-30$11.85B$12.48B$12.85B2
2027-12-31$11.86B$12.49B$12.87B2

EPS Estimates

PeriodLowAvgHigh#
2026-09-30$1.36$1.46$1.521
2026-12-31$0.76$0.81$0.851
2027-03-31$1.23$1.31$1.361
2027-06-30$1.32$1.41$1.471
2027-09-30$1.53$1.64$1.711
2027-12-31$0.77$0.82$0.861

Frequently Asked Questions

What is the analyst consensus for GSK?

The consensus among 1 analysts covering GSK plc (GSK) is Sell with an average price target of $52.45.

What is the highest price target for GSK?

The highest analyst price target for GSK is $85.00.

What is the lowest price target for GSK?

The lowest analyst price target for GSK is $35.25.

How many analysts cover GSK?

1 analysts have issued ratings for GSK plc in the past 12 months.

Is GSK a buy or sell right now?

Based on 1 analyst ratings, GSK has a consensus rating of Sell (4.00/5) with a +19.7% upside to the consensus target of $52.45.

What are the earnings estimates for GSK?

Analysts estimate GSK will report EPS of $1.46 for the period ending 2026-09-30, with revenue estimated at $12.04B.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.